HANSOH PHARMA (03692): Injection of Reconnective Votutamab (HS-20093) for the treatment of osteosarcoma included in the priority review and approval process of the National Medical Products Administration
HANSOH PHARMA (03692) announced that on September 14, 2026, based on the positive results of the pivotal Phase III trial ARTEMIS-011 of HS-20093 for injection (reconnective votutamab for injection) (the Product), the indication of the Product for the treatment of osteosarcoma patients aged 12 years who have failed at least two prior lines of therapy has been included in the priority review and approval process of China's National Medical Products Administration (NMPA).
HANSOH PHARMA (03692) announced that on September 14, 2026, based on the positive results of the pivotal Phase III trial ARTEMIS-011 of HS-20093 for injection (reconnective votutamab for injection) (the product), the indication of the product for the treatment of osteosarcoma patients aged 12 years who have failed at least two prior lines of therapy has been included in the priority review and approval process of China's National Medical Products Administration (NMPA).
Related Articles
CHAOJU EYE CARE (02219) repurchased 24,500 shares for HK$60,800 on September 22.
LBX Pharmacy Chain Joint Stock (603883.SH) plans to contribute 50 million yuan to participate in the Ningbo Zhixing Yueheng Fund.
FUTURE DATA(08229): Auditor renamed as "Silian Bychun CPA Limited"
CHAOJU EYE CARE (02219) repurchased 24,500 shares for HK$60,800 on September 22.
LBX Pharmacy Chain Joint Stock (603883.SH) plans to contribute 50 million yuan to participate in the Ningbo Zhixing Yueheng Fund.
FUTURE DATA(08229): Auditor renamed as "Silian Bychun CPA Limited"
